Dutch researchers employed a 'genome mining' approach to activate a group of genes in the bacterium Streptomyces coelicolor.
Dutch researchers employed a 'genome mining' approach to activate a group of genes in the bacterium Streptomyces coelicolor. This led to the production of a new antibacterial compound that is effective against several bacterial strains, including Escherichia coli.
The study, by scientists at the University of Groningen, The Netherlands, appears in the August issue of Microbiology.
The findings could lead to new treatments for serious diseases that are rapidly acquiring multi-drug resistance.
Streptomyces is a common soil bacterium that is well-known for its antibiotic-producing capabilities. In 2002, genomic sequencing of one Streptomyces species, S. coelicolor, revealed several groups of genes whose function was unknown.
By digging deeper and removing a molecule that specifically inactivates one of the mystery gene groups, known as cpk, the researchers in this study were able to 'awaken' the genes, to find that they produced the new antibiotic, in addition to a bright yellow pigment.
This is the first time a genome mining approach to drug discovery has been successfully used in Streptomyces.
Advertisement
The same approach for 'awakening' new antibiotic production pathways could also be used to tap other micro-organisms, such as filamentous fungi, for sources of biologically active compounds. Aside from antibiotics, these compounds may include other antimicrobials or antitumour agents.
Advertisement
Source-ANI